PhtX Protein Vaccine Broadens Pneumococcal Serotype Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Streptococcus pneumoniae do not effectively cover all serotypes, particularly in regions with different dominant serotypes, and there is a need for vaccines that target specific pneumococcal diseases with optimal protection, as existing vaccines may not provide comprehensive coverage and are influenced by varying zinc and manganese levels in different infection sites.
Innovation Solution
An immunogenic composition comprising a pharmaceutically effective amount of isolated PhtX protein, specifically PhtA, PhtB, PhtD, or PhtE, is used to treat or prevent Streptococcus pneumoniae infections in environments with low zinc and manganese concentrations, upregulating the expression of these proteins in the bacteria, thereby enhancing protection against infections in the blood, lung, ear, or meninges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serotype-specific vaccines are used, then protection against specific serotypes is improved, but coverage against all serotypes deteriorates
Solution Approach 1:
The patent uses universal antigens (Pht proteins and CbpA) that are shared across multiple pneumococcal serotypes. These proteins are conserved among different serotypes, allowing a single vaccine formulation to provide broad-spectrum protection against diverse serotypes rather than requiring separate serotype-specific vaccines.
Solution Approach 2:
The patent changes the target parameter from serotype-specific polysaccharides to conserved protein antigens with universal protective function. By targeting proteins that are identical or highly similar across serotypes, the vaccine achieves broad coverage while maintaining reliable protection through conserved epitopes.
2Productivity
If zinc and manganese levels are high in infection environment, then bacterial growth is promoted, but PhtX protein expression is downregulated
Solution Approach 1:
The vaccine administers PhtX proteins or nucleic acids encoding these proteins before infection occurs. This preliminary immunization ensures that protective antibodies are present in the host before the bacterial infection establishes, overcoming the fact that bacterial PhtX expression is low in high-zinc environments like blood.
Solution Approach 2:
The patent uses the host immune system as an intermediary to deliver protection. Rather than relying on bacterial PhtX expression in the infection environment, the vaccine induces host antibodies that mediate protection against all serotypes, bypassing the zinc-dependent expression limitation.
Data Source
Figure 1
Figure 2(a)~2(e)
Figure 3(a)~3(e)
AI summary
The present invention discloses a method of treating or preventing a Streptococcus pneumoniae infection wherein the Streptococcus pneumoniae infection occurs in an environment where the free concentration of Zn2+ and/or Mn2+ is sufficiently low to upregulate the expression of at least one PhtX protein (for example PhtD) in the Streptococcus pneumoniae; comprising the step of administering a pharmaceutically effective amount of the PhtX protein to a human patient.